Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Standard
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. / Press, Michael F; Sauter, Guido; Buyse, Marc; Bernstein, Leslie; Guzman, Roberta; Santiago, Angela; Villalobos, Ivonne E; Eiermann, Wolfgang; Pienkowski, Tadeusz; Martin, Miguel; Robert, Nicholas; Crown, John; Bee, Valerie; Taupin, Henry; Flom, Kerry J; Tabah-Fisch, Isabelle; Pauletti, Giovanni; Lindsay, Mary-Ann; Riva, Alessandro; Slamon, Dennis J.
In: J CLIN ONCOL, Vol. 29, No. 7, 7, 2011, p. 859-867.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
AU - Press, Michael F
AU - Sauter, Guido
AU - Buyse, Marc
AU - Bernstein, Leslie
AU - Guzman, Roberta
AU - Santiago, Angela
AU - Villalobos, Ivonne E
AU - Eiermann, Wolfgang
AU - Pienkowski, Tadeusz
AU - Martin, Miguel
AU - Robert, Nicholas
AU - Crown, John
AU - Bee, Valerie
AU - Taupin, Henry
AU - Flom, Kerry J
AU - Tabah-Fisch, Isabelle
AU - Pauletti, Giovanni
AU - Lindsay, Mary-Ann
AU - Riva, Alessandro
AU - Slamon, Dennis J
PY - 2011
Y1 - 2011
N2 - Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers.
AB - Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers.
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Treatment Outcome
KW - Prognosis
KW - Risk Assessment
KW - Survival Analysis
KW - Disease-Free Survival
KW - Proportional Hazards Models
KW - Genetic Predisposition to Disease
KW - Gene Expression Regulation, Neoplastic
KW - Statistics, Nonparametric
KW - In Situ Hybridization, Fluorescence
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
KW - Anthracyclines/administration & dosage
KW - Antigens, Neoplasm/drug effects/genetics
KW - Breast Neoplasms/drug therapy/genetics/mortality
KW - DNA Topoisomerases, Type II/drug effects/genetics
KW - DNA-Binding Proteins/drug effects/genetics
KW - Gene Amplification/drug effects
KW - Genes, erbB-2/drug effects
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Treatment Outcome
KW - Prognosis
KW - Risk Assessment
KW - Survival Analysis
KW - Disease-Free Survival
KW - Proportional Hazards Models
KW - Genetic Predisposition to Disease
KW - Gene Expression Regulation, Neoplastic
KW - Statistics, Nonparametric
KW - In Situ Hybridization, Fluorescence
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
KW - Anthracyclines/administration & dosage
KW - Antigens, Neoplasm/drug effects/genetics
KW - Breast Neoplasms/drug therapy/genetics/mortality
KW - DNA Topoisomerases, Type II/drug effects/genetics
KW - DNA-Binding Proteins/drug effects/genetics
KW - Gene Amplification/drug effects
KW - Genes, erbB-2/drug effects
M3 - SCORING: Journal article
VL - 29
SP - 859
EP - 867
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 7
M1 - 7
ER -